WILMINGTON, N.C., March 27 /PRNewswire-FirstCall/ -- PPD, Inc. today announced the opening of offices in Athens, Greece, and Seattle, Washington, as the company continues to expand its global footprint for the delivery of clinical development services in response to increasing client demand.
Both offices serve as hubs for previously regional-based employees in providing development services for Phase II-IV studies in key therapeutic areas. The office in Athens focuses on patient recruitment, clinical monitoring and regulatory support while the Seattle office houses clinical monitoring and project management teams.
"The new offices enable us to address the organic growth of our business driven by client needs for Phase II-IV services as well as enhance support for our employees located in these areas," said Fred Eshelman, chief executive officer of PPD. "We plan continued investment in infrastructure, systems and people to align with the global research needs of our clients."
The PPD office in Athens is located at Kifissias Avenue and Sofokleous Street, and the Seattle office is located within the downtown landmark Columbia Center at 701 5th Avenue. For more information about PPD services offered through the Athens office, call +44 1223 374 430; and for Seattle, call +910 558 6789.
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 28 countries and more than 9,100 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at http://www.ppdi.com/.
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the opening of new offices and continued plans for expansion contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; the ability to attract and retain key personnel; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.
